Analysis of antimicrobial resistance patterns and genetic mutations in Helicobacter pylori from West Bengal, India depicting escalating clarithromycin and high levofloxacin resistance.

IF 4 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Sangita Paul, Bipul Chandra Karmakar, Nirupam Roy, Sujit Chaudhuri, Asish Kumar Mukhopadhyay
{"title":"Analysis of antimicrobial resistance patterns and genetic mutations in Helicobacter pylori from West Bengal, India depicting escalating clarithromycin and high levofloxacin resistance.","authors":"Sangita Paul, Bipul Chandra Karmakar, Nirupam Roy, Sujit Chaudhuri, Asish Kumar Mukhopadhyay","doi":"10.1186/s13099-025-00744-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The growing resistance of Helicobacter pylori (H. pylori) to antibiotics poses a significant global health challenge, particularly in developing regions where infection rates are high, and routine antibiotic susceptibility surveillance is limited. This study aimed to evaluate the antimicrobial resistance patterns and associated genetic mutations in H. pylori strains isolated from patients in West Bengal (WB), India.</p><p><strong>Methods: </strong>A total of 88 H. pylori strains were isolated from gastric biopsy samples collected between 2018 and 2020 from patients diagnosed with gastritis, duodenal ulcer, or gastric cancer. Antimicrobial susceptibility was determined using the agar dilution method against six antibiotics: metronidazole, tetracycline, clarithromycin, furazolidone, levofloxacin, and amoxicillin. Resistance-associated mutations in gyrA (levofloxacin), frxA and rdxA (metronidazole), and pbp1A (amoxicillin) were characterized via Sanger sequencing. Mutations in the 23SrRNA gene, implicated in clarithromycin resistance, were identified through allele-specific PCR, validated by Sanger sequencing and transformation assays. Additionally, BsaI and BbsI restriction enzyme digestion was used to confirm specific point mutations in 23SrRNA gene of clarithromycin-resistant isolates.</p><p><strong>Results: </strong>Of 210 biopsies analyzed, 79 (37.6%) were H. pylori-positive, yielding 88 distinct strains-some patients harbored multiple genetically diverse isolates, identified by differences in cagA/vacA genotypes and antibiotic resistance profiles. Although, no association was found between virulence gene profile and resistance pattern. Resistance rates were highest for levofloxacin (69.3%), followed by metronidazole (61.4%) and clarithromycin (19.3%). Nearly all clarithromycin-resistant isolates carried the A2143G mutation in the 23SrRNA gene, capable of getting naturally transmitted into the next generations also. Levofloxacin-resistant strains harbored mutations in GyrA at codons 63, 87, 88, 91, 130, and 150, and a novel Gly85Ala substitution was identified. Metronidazole resistance correlated more strongly with rdxA mutations than with frxA. No resistance was detected against furazolidone and tetracycline, while amoxicillin resistance was rare (1.1%). Multidrug resistance was observed in 10.2% of isolates, with 32.9% displaying dual resistance to metronidazole + levofloxacin, and 6.8% to clarithromycin + levofloxacin.</p><p><strong>Conclusions: </strong>High clarithromycin, substantial metronidazole and levofloxacin resistance in H. pylori strains from WB underscore the urgent need to revise empirical treatment strategies. These findings advocate for localized, resistance-guided therapy protocols and reinforce the importance of continuous antimicrobial surveillance to optimize treatment outcomes and mitigate resistance development.</p>","PeriodicalId":12833,"journal":{"name":"Gut Pathogens","volume":"17 1","pages":"71"},"PeriodicalIF":4.0000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12465208/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gut Pathogens","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13099-025-00744-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The growing resistance of Helicobacter pylori (H. pylori) to antibiotics poses a significant global health challenge, particularly in developing regions where infection rates are high, and routine antibiotic susceptibility surveillance is limited. This study aimed to evaluate the antimicrobial resistance patterns and associated genetic mutations in H. pylori strains isolated from patients in West Bengal (WB), India.

Methods: A total of 88 H. pylori strains were isolated from gastric biopsy samples collected between 2018 and 2020 from patients diagnosed with gastritis, duodenal ulcer, or gastric cancer. Antimicrobial susceptibility was determined using the agar dilution method against six antibiotics: metronidazole, tetracycline, clarithromycin, furazolidone, levofloxacin, and amoxicillin. Resistance-associated mutations in gyrA (levofloxacin), frxA and rdxA (metronidazole), and pbp1A (amoxicillin) were characterized via Sanger sequencing. Mutations in the 23SrRNA gene, implicated in clarithromycin resistance, were identified through allele-specific PCR, validated by Sanger sequencing and transformation assays. Additionally, BsaI and BbsI restriction enzyme digestion was used to confirm specific point mutations in 23SrRNA gene of clarithromycin-resistant isolates.

Results: Of 210 biopsies analyzed, 79 (37.6%) were H. pylori-positive, yielding 88 distinct strains-some patients harbored multiple genetically diverse isolates, identified by differences in cagA/vacA genotypes and antibiotic resistance profiles. Although, no association was found between virulence gene profile and resistance pattern. Resistance rates were highest for levofloxacin (69.3%), followed by metronidazole (61.4%) and clarithromycin (19.3%). Nearly all clarithromycin-resistant isolates carried the A2143G mutation in the 23SrRNA gene, capable of getting naturally transmitted into the next generations also. Levofloxacin-resistant strains harbored mutations in GyrA at codons 63, 87, 88, 91, 130, and 150, and a novel Gly85Ala substitution was identified. Metronidazole resistance correlated more strongly with rdxA mutations than with frxA. No resistance was detected against furazolidone and tetracycline, while amoxicillin resistance was rare (1.1%). Multidrug resistance was observed in 10.2% of isolates, with 32.9% displaying dual resistance to metronidazole + levofloxacin, and 6.8% to clarithromycin + levofloxacin.

Conclusions: High clarithromycin, substantial metronidazole and levofloxacin resistance in H. pylori strains from WB underscore the urgent need to revise empirical treatment strategies. These findings advocate for localized, resistance-guided therapy protocols and reinforce the importance of continuous antimicrobial surveillance to optimize treatment outcomes and mitigate resistance development.

印度西孟加拉邦幽门螺杆菌的抗微生物药物耐药性模式和基因突变分析表明,克拉霉素和左氧氟沙星的耐药性不断上升。
背景:幽门螺杆菌(h.p ylori)对抗生素的耐药性日益增强,对全球健康构成了重大挑战,特别是在感染率高且常规抗生素敏感性监测有限的发展中地区。本研究旨在评估从印度西孟加拉邦(WB)患者中分离的幽门螺杆菌菌株的抗微生物药物耐药性模式和相关基因突变。方法:从2018年至2020年诊断为胃炎、十二指肠溃疡或胃癌的患者的胃活检样本中分离出88株幽门螺杆菌。采用琼脂稀释法测定对甲硝唑、四环素、克拉霉素、呋喃唑酮、左氧氟沙星和阿莫西林6种抗生素的敏感性。通过Sanger测序鉴定了gyrA(左氧氟沙星)、frxA和rdxA(甲硝唑)以及pbp1A(阿莫西林)的耐药相关突变。通过等位基因特异性PCR鉴定了与克拉霉素耐药有关的23SrRNA基因突变,并通过Sanger测序和转化试验进行了验证。此外,利用BsaI和BbsI酶切法确定了克拉霉素耐药菌株23SrRNA基因的特异性点突变。结果:在分析的210份活检中,79份(37.6%)为幽门螺杆菌阳性,产生88种不同的菌株——一些患者携带多种遗传多样性的分离株,通过cagA/vacA基因型和抗生素耐药性谱的差异来鉴定。然而,没有发现毒力基因谱与抗性模式之间的关联。耐药率最高的是左氧氟沙星(69.3%),其次是甲硝唑(61.4%)和克拉霉素(19.3%)。几乎所有耐克拉霉素的分离株都携带23SrRNA基因中的A2143G突变,也能够自然地传播给下一代。左氧氟沙星耐药菌株在GyrA密码子63、87、88、91、130和150处发生突变,并鉴定出新的Gly85Ala取代。甲硝唑耐药性与rdxA突变的相关性强于与frxA突变的相关性。对呋喃唑酮和四环素均无耐药,对阿莫西林耐药少见(1.1%)。其中对甲硝唑+左氧氟沙星双耐药32.9%,对克拉霉素+左氧氟沙星双耐药6.8%。结论:WB幽门螺旋杆菌对克拉霉素、甲硝唑和左氧氟沙星的高耐药,表明迫切需要修改经验治疗策略。这些发现提倡采用局部的、以耐药性为导向的治疗方案,并强调了持续进行抗菌药物监测以优化治疗结果和减轻耐药性发展的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Gut Pathogens
Gut Pathogens GASTROENTEROLOGY & HEPATOLOGY-MICROBIOLOGY
CiteScore
7.70
自引率
2.40%
发文量
43
期刊介绍: Gut Pathogens is a fast publishing, inclusive and prominent international journal which recognizes the need for a publishing platform uniquely tailored to reflect the full breadth of research in the biology and medicine of pathogens, commensals and functional microbiota of the gut. The journal publishes basic, clinical and cutting-edge research on all aspects of the above mentioned organisms including probiotic bacteria and yeasts and their products. The scope also covers the related ecology, molecular genetics, physiology and epidemiology of these microbes. The journal actively invites timely reports on the novel aspects of genomics, metagenomics, microbiota profiling and systems biology. Gut Pathogens will also consider, at the discretion of the editors, descriptive studies identifying a new genome sequence of a gut microbe or a series of related microbes (such as those obtained from new hosts, niches, settings, outbreaks and epidemics) and those obtained from single or multiple hosts at one or different time points (chronological evolution).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信